Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oncology
Analyst Available to Comment on Impact to the Pharmaceutical Industry of U.S. Senate Committee Approval of Biogenerics Legislation
July 10th, 2007
Andrew Merseth, analyst at Decision Resources is available to comment on the impact to the pharmaceutical industry of the U.S. Senate committee's approval of biogenerics legislation. A U.S. Senate committee voted on Wednesday in favor of legislation that would allow the FDA to approve biogeneric drugs, and the bill, "The Biologics Price Competition and Innovation Act of 2007," will now head for the Senate floor. Biotechnology firms who oppose the bill have suggested that their products are too difficult to copy without risking dangerous side effects. Decision Resources recently conducted a survey at the annual meeting of the American Society of Clinical Oncology (ASCO)...
Source: Drug Law Weekly (2007-07-10)
|
